Literature DB >> 19933955

Meta-analysis of the impact of 9 medication classes on falls in elderly persons.

John C Woolcott1, Kathryn J Richardson, Matthew O Wiens, Bhavini Patel, Judith Marin, Karim M Khan, Carlo A Marra.   

Abstract

BACKGROUND: There is increasing recognition that the use of certain medications contributes to falls in seniors. Our objective was to update a previously completed meta-analysis looking at the association of medication use and falling to include relevant drug classes and new studies that have been completed since a previous meta-analysis.
METHODS: Studies were identified through a systematic search of English-language articles published from 1996 to 2007. We identified studies that were completed on patients older than 60 years, looking at the association between medication use and falling. Bayesian methods allowed us to combine the results of a previous meta-analysis with new information to estimate updated Bayesian odds ratios (ORs) and 95% credible intervals (95% CrIs)
RESULTS: Of 11 118 identified articles, 22 met our inclusion criteria. Meta-analyses were completed on 9 unique drug classes, including 79 081 participants, with the following Bayesian unadjusted OR estimates: antihypertensive agents, OR, 1.24 (95% CrI, 1.01-1.50); diuretics, OR, 1.07 (95% CrI, 1.01-1.14); beta-blockers, OR, 1.01 (95% CrI, 0.86-1.17); sedatives and hypnotics, OR, 1.47 (95% CrI, 1.35-1.62); neuroleptics and antipsychotics, OR, 1.59 (95% CrI, 1.37-1.83); antidepressants, OR, 1.68 (95% CrI, 1.47-1.91); benzodiazepines, OR, 1.57 (95% CrI, 1.43-1.72); narcotics, OR, 0.96 (95% CrI, 0.78-1.18); and nonsteroidal anti-inflammatory drugs, OR, 1.21 (95% CrI, 1.01-1.44). The updated Bayesian adjusted OR estimates for diuretics, neuroleptics and antipsychotics, antidepressants, and benzodiazepines were 0.99 (95% CrI, 0.78-1.25), 1.39 (95% CrI, 0.94-2.00), 1.36 (95% CrI, 1.13-1.76), and 1.41 (95% CrI, 1.20-1.71), respectively. Stratification of studies had little effect on Bayesian OR estimates, with only small differences in the stratified ORs observed across population (for beta-blockers and neuroleptics and antipsychotics) and study type (for sedatives and hypnotics, benzodiazepines, and narcotics). An increased likelihood of falling was estimated for the use of sedatives and hypnotics, neuroleptics and antipsychotics, antidepressants, benzodiazepines, and nonsteroidal anti-inflammatory drugs in studies considered to have "good" medication and falls ascertainment.
CONCLUSION: The use of sedatives and hypnotics, antidepressants, and benzodiazepines demonstrated a significant association with falls in elderly individuals.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19933955     DOI: 10.1001/archinternmed.2009.357

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  371 in total

1.  Medication-related fall incidents in an older, ambulant population: the B-PROOF study.

Authors:  Annelies C Ham; Karin M A Swart; Anke W Enneman; Suzanne C van Dijk; Sadaf Oliai Araghi; Janneke P van Wijngaarden; Nikita L van der Zwaluw; Elske M Brouwer-Brolsma; Rosalie A M Dhonukshe-Rutten; Natasja M van Schoor; Tischa J M van der Cammen; Paul Lips; Lisette C P G M de Groot; André G Uitterlinden; Renger F Witkamp; Bruno H Stricker; Nathalie van der Velde
Journal:  Drugs Aging       Date:  2014-12       Impact factor: 3.923

2.  Serotonin-norepinephrine reuptake inhibitor antidepressants and the risk of falls in older people: case-control and case-series analysis of a large UK primary care database.

Authors:  Jonathan Gribbin; Richard Hubbard; John Gladman; Chris Smith; Sarah Lewis
Journal:  Drugs Aging       Date:  2011-11-01       Impact factor: 3.923

3.  The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.

Authors:  P B Rosenberg; M M Mielke; D Han; J S Leoutsakos; C G Lyketsos; P V Rabins; P P Zandi; J C S Breitner; M C Norton; K A Welsh-Bohmer; I H Zuckerman; G B Rattinger; R C Green; C Corcoran; J T Tschanz
Journal:  Int J Geriatr Psychiatry       Date:  2012-02-29       Impact factor: 3.485

4.  Arousal, valence and their relative effects on postural control.

Authors:  Brian C Horslen; Mark G Carpenter
Journal:  Exp Brain Res       Date:  2011-09-27       Impact factor: 1.972

5.  Self-perception of fracture risk: what can it tell us?

Authors:  A E Litwic; J E Compston; A Wyman; E S Siris; S H Gehlbach; J D Adachi; R Chapurlat; A Díez-Pérez; A Z LaCroix; J W Nieves; J C Netelenbos; J Pfeilschifter; M Rossini; C Roux; K G Saag; S Silverman; N B Watts; S L Greenspan; L March; C L Gregson; C Cooper; E M Dennison
Journal:  Osteoporos Int       Date:  2017-08-31       Impact factor: 4.507

6.  Association between prescribing of cardiovascular and psychotropic medications and hospital admission for falls or fractures.

Authors:  Rupert A Payne; Gary A Abel; Colin R Simpson; Simon R J Maxwell
Journal:  Drugs Aging       Date:  2013-04       Impact factor: 3.923

7.  Long-term risk of hip or forearm fractures in older occasional users of benzodiazepines.

Authors:  Hélène Carrier; Sébastien Cortaredona; Viviane Philipps; Hélène Jacqmin-Gadda; Marie Tournier; Hélène Verdoux; Pierre Verger
Journal:  Br J Clin Pharmacol       Date:  2020-05-10       Impact factor: 4.335

Review 8.  [List-based concepts in pharmacotherapy of older and geriatric patients].

Authors:  Ulrich Thiem
Journal:  Z Gerontol Geriatr       Date:  2018-05-03       Impact factor: 1.281

9.  Association of the Centers for Medicare & Medicaid Services' National Partnership to Improve Dementia Care With the Use of Antipsychotics and Other Psychotropics in Long-term Care in the United States From 2009 to 2014.

Authors:  Donovan T Maust; H Myra Kim; Claire Chiang; Helen C Kales
Journal:  JAMA Intern Med       Date:  2018-05-01       Impact factor: 21.873

Review 10.  A practical approach to the pharmacological management of hypertension in older people.

Authors:  Nikesh Parekh; Amy Page; Khalid Ali; Kevin Davies; Chakravarthi Rajkumar
Journal:  Ther Adv Drug Saf       Date:  2016-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.